What potential therapy reports out next? There are not a lot of large, late stage, Alzheimer’s trial results expected until 2019 (including Biogen’s aducanumab, Merck’s BACE- oriented verubecestat, and Lilly/AstraZeneca’s lanabecestat). Post navigationPreviousPrevious post:LSD1 Protects Against Hippocampal and Cortical NeurodegenerationNextNext post:In Nature this week: Blocking ApoE4 in brain may prevent nerve cell death, inflammation